BTTX vs. APVO, ADTX, SXTC, NVTA, MOTS, SIENQ, SQZ, SMFL, CMRA, and HSTO
Should you be buying Better Therapeutics stock or one of its competitors? The main competitors of Better Therapeutics include Aptevo Therapeutics (APVO), Aditxt (ADTX), China SXT Pharmaceuticals (SXTC), Invitae (NVTA), Motus GI (MOTS), Sientra (SIENQ), SQZ Biotechnologies (SQZ), Smart for Life (SMFL), Comera Life Sciences (CMRA), and Histogen (HSTO). These companies are all part of the "medical" sector.
Aptevo Therapeutics (NASDAQ:APVO) and Better Therapeutics (NASDAQ:BTTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.
Aptevo Therapeutics' return on equity of 0.00% beat Better Therapeutics' return on equity.
Better Therapeutics has a consensus price target of $6.00, indicating a potential upside of 53,711.66%. Given Aptevo Therapeutics' higher probable upside, analysts plainly believe Better Therapeutics is more favorable than Aptevo Therapeutics.
Aptevo Therapeutics has higher revenue and earnings than Better Therapeutics.
Aptevo Therapeutics received 193 more outperform votes than Better Therapeutics when rated by MarketBeat users. Likewise, 52.66% of users gave Aptevo Therapeutics an outperform vote while only 41.67% of users gave Better Therapeutics an outperform vote.
8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 0.3% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Aptevo Therapeutics has a beta of 5.13, meaning that its share price is 413% more volatile than the S&P 500. Comparatively, Better Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.
In the previous week, Aptevo Therapeutics had 2 more articles in the media than Better Therapeutics. MarketBeat recorded 5 mentions for Aptevo Therapeutics and 3 mentions for Better Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.03 beat Better Therapeutics' score of -0.18 indicating that Better Therapeutics is being referred to more favorably in the news media.
Summary
Aptevo Therapeutics beats Better Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Better Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Better Therapeutics Competitors List
Related Companies and Tools
